Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab Extension Study in CSU
NCT04210843Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 45
01
Overview
A Phase 3 trial of ligelizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Apr 2020; status: terminated.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04210843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210843.